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Abstract 
Objective  
To characterise the clinical features of children and young people admitted to hospital 
with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection in the UK, and explore factors associated with admission to critical 
care, mortality, and development of multisystem inflammatory syndrome in children 
and adolescents temporarily related to covid-19 (MIS-C).  
Design  
Prospective observational cohort study with rapid data gathering and near real time 
analysis. 
Setting  
260 acute care hospitals in England, Wales, and Scotland between 17th January and 
5th June 2020, with a minimal follow-up time of two weeks (to 19th June 2020). 
Participants  
451 children and young people aged less than 19 years admitted to 116 hospitals and 
enrolled into the International Severe Acute Respiratory and emergency Infections 
Consortium (ISARIC) WHO Clinical Characterisation Protocol UK study with 
laboratory-confirmed SARS-CoV-2. 
Main Outcome Measures  
Admission to critical care (high dependency or intensive care), in-hospital mortality, 
or meeting the WHO preliminary case definition for MIS-C. 
Results  
Median age was 3.9 years [interquartile range (IQR) 0.3-12.9 years], 36% (162/451) 
were under 12 months old, and 57% (256/450) were male. 56% (224/401) were 
White, 12% (49/401) South Asian and 10% (40/401) Black. 43% (195/451) had at 
least one recorded comorbidity. A muco-enteric cluster of symptoms was identified, 
closely mirroring the WHO MIS-C criteria. 
17% of children (72/431) were admitted to critical care. On multivariable analysis this 
was associated with age under one month odds ratio 5.05 (95% confidence interval 
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1.69 to 15.72, p=0.004), age 10 to 14 years OR 3.11 (1.21 to 8.55, p=0.022) and 
Black ethnicity OR 3.02 (1.30 to 6.84, p=0.008). Three young people died (0.7 %, 
3/451) aged 16 to 19 years, all of whom had profound comorbidity.  
Twelve percent of children (36/303) met the WHO MIS-C criteria, with the first 
patient developing symptoms in mid-March. Those meeting MIS-C criteria were 
older, (median age 10.8 years ([IQR 8.4-14.1] vs 2.0 [0.2-12.6]), p<0.001) and more 
likely to be of non-White ethnicity (70% (23/33) vs 43% (101/237), p=0.005). 
Children with MIS-C were four times more likely to be admitted to critical care (61% 
(22/36) vs 15% (40/267, p<0.001). In addition to the WHO criteria, children with 
MIS-C were more likely to present with headache (45% (13/29) vs 11% (19/171), 
p<0.001), myalgia (39% (11/28) vs 7% (12/170), p<0.001), sore throat (37% (10/27) 
vs (13% (24/183, p = 0.004) and fatigue (57% (17/30)  vs 31% (60/192), p =0.012) 
than children who did not and to have a platelet count of less than 150 x109/L (30% 
(10/33) vs 10% (24/232), p=0.004). 
  
Conclusions  
Our data confirms less severe covid-19 in children and young people than in adults 
and we provide additional evidence for refining the MIS-C case definition. The 
identification of a muco-enteric symptom cluster also raises the suggestion that MIS-
C is the severe end of a spectrum of disease.  
Study registration ISRCTN66726260 
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Introduction 
Children and young people comprise only 1-2% of covid-19 cases worldwide [1–3]. 
In contrast to other respiratory viruses, children appear to have a lower risk of 
infection than adults [4] and the vast majority of reported infections in children are 
reported as mild or asymptomatic, with few recorded childhood fatalities attributed to 
covid-19 [2,5–7]. Initial reports from China showed only 0.6% of children with covid-
19 were critically ill [5].  
A severe disease phenotype has emerged in children which appears temporally 
associated with SARS-CoV-2 infection [8,9]. The condition was first described in 
May 2020 in a cluster of children admitted to critical care in South London (UK) with 
evidence of a multisystem hyperinflammatory state with features similar to Kawasaki 
disease and toxic shock syndrome [8]. These children required inotropic support for 
refractory circulatory shock and mechanical ventilation for cardiovascular 
stabilisation rather than respiratory failure. Similar cohorts have been reported in Italy 
[10] and France [11]. The European Centre for Disease Prevention and Control on 
15th May 2020 estimated around 230 children had presented with this new syndrome 
in EU/EEA countries with two fatalities [3]. Preliminary case definitions have been 
proposed by the WHO [9] and the Royal College of Paediatrics and Child Health 
(RCPCH) [12]. The WHO use the term multisystem inflammatory syndrome in 
children and adolescents temporarily related to covid-19 (MIS-C) while RCPCH 
describe this illness as Paediatric Inflammatory Multisystem Syndrome temporally 
associated with SARS-COV-2 (PIMS-TS). 
We aimed to characterise the features of children and young people (aged less than 19 
years old) admitted to hospital in the UK with laboratory-confirmed SARS-CoV-2 
from the International Severe Acute Respiratory and emerging Infection Consortium  
(ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) cohort. Since our 
study enrolled patients prospectively from the beginning of the pandemic, we also had 
a unique opportunity to examine the emergence, timing, risk factors, clinical 
presentation, progression, course and outcomes of children and young people meeting 
the WHO preliminary case definition for MIS-C [9].  
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Methods  
Study design and setting 
The ISARIC WHO CCP-UK is an ongoing prospective cohort study across acute care 
hospitals in England, Wales and Scotland (8). This standing protocol for studying 
disease caused by pathogens of public health interest was activated on 17th January 
2020. The protocol, associated documents, and detail of the Independent Data and 
Material Access Committee (IDAMAC) are available at https://isaric4c.net. STROBE 
guidelines were used when reporting. 
Participants 
Patients of any age admitted to hospital with proven or high likelihood of SARS-
CoV-2 infection were enrolled into the ISARIC WHO CCP-UK cohort as previously 
described [13]. We present the data from children and young people aged less than 19 
years old on the date of hospital admission, enrolled into the study up to and including 
5th June 2020, who had at least two weeks of outcome data available, and who had 
documented laboratory evidence of a positive result for SARS-CoV-2 (by PCR or 
serology). Patients who were already admitted for other clinical reasons and 
subsequently tested positive for SARS-CoV-2 whilst an inpatient were also included 
in this cohort.  
Data collection  
Demographic and baseline data (including comorbidities and regular medications 
taken) alongside data pertaining to symptoms, clinical signs (including vital signs) 
during admission, laboratory and pathology investigations, treatments received whilst 
admitted and outcome were collected onto case report forms (supplement available 
online). Data regarding illness progression and severity, including location within the 
hospital (ward vs. critical care) were collected on day 1 (admission/diagnosis), days 3, 
6, and 9, admission to critical care and on discharge/death. Data were collected from 
healthcare records onto the case report forms through a secure online database, 
REDCap (Research Electronic Data Capture, Vanderbilt University, hosted by the 
University of Oxford (UK)). Collection of this routine anonymised demographic and 
clinical data from medical records did not require consent in England and Wales. In 
Scotland, a waiver for consent was obtained from the Public Benefit and Privacy 
Panel.  
Variables 
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The case report form was agnostic to patient age and as such existing comorbidity 
variables were not tailored to the paediatric population (see Supp Methods for case 
report form and recoding of paediatric variables). Ethnicity was self-reported and 
transcribed from the healthcare record. The Paediatric Early Warning Score (PEWS) 
was used as a measure of disease severity at admission [14].  
Criteria for diagnosis of Multisystem Inflammatory Syndrome in Children and 
Adolescents (MIS-C) 
The WHO preliminary case definition for MIS-C [9] was used as a framework for 
identifying children with the syndrome within this dataset (box 1).  
 
1. Fever for 3 days or more (of any duration, self-reported prior to presentation) 
2. Plus two of the following:                                                   
a. Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammatory 
signs (self-reported rash / conjunctivitis) 
b. Hypotension or shock (age < 2 years systolic blood pressure < 60 mmHg; ≥2 
and < 5 years <70 mmHg; ≥ 5 and < 12 years <80 mmHg; ≥ 12 years < 90 
mmHg at any point in admission [14]) 
c. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary 
abnormalities (diagnosis of endocarditis or myocarditis or documented 
pericardial effusion, coronary artery aneurysm, cardiomegaly or cardiac 
dysfunction on echocardiography) 
d. Evidence of coagulopathy (INR > 1.2 (any age [15]); age ≤3 months and PT 
>14s; age > 3 months and PT > 12s [16])  
e. Acute gastrointestinal problems (self-reported diarrhoea, vomiting, or 
abdominal pain) 
3. Plus elevated markers of inflammation (CRP ≥ 60 mg/L or ferritin ≥ 200 mg/L 
at any point during admission; cut offs chosen after expert discussion) 
4. Plus no other obvious microbial cause of inflammation (no significant positive 
growth on blood culture / cerebrospinal fluid culture during admission) 
Box 1. WHO preliminary case definition for MIS-C with adaptations in italics to 
allow case identification in the ISARIC WHO CCP-UK cohort. 
 
Outcomes 
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The primary outcomes of this study were critical care admission (high dependency 
unit (HDU) or intensive care unit (ICU)), development of MIS-C, and in-hospital 
mortality. Requirement for respiratory and cardiovascular support were also 
examined. A minimum two-week follow-up time was ensured for all included 
patients.  
Bias 
Specialist children’s hospitals (tertiary-care) with paediatric-specific research teams 
may be over-represented. Capacity to enrol was also limited by staff resources at 
times of high covid-19 activity, and we were unable to comment on patients not 
recruited. 
Missing data 
The pandemic disrupted routine care and usual research activities limiting data 
collection and verification, particularly during the peak of outbreak activity. We did 
not impute missing data for this descriptive analysis. To reduce the impact of missing 
data on outcome analyses, we restricted these analyses to patients who had been 
admitted for at least two weeks before data extraction. Complete data were not 
available for all variables, hence denominators differ between analyses.  
Statistical analysis  
Continuous variables are displayed as mean (standard deviation) or median 
(interquartile range) if non-normally distributed. Categorical variables are presented 
as a frequency (percentage) unless otherwise stated. For univariable comparisons, we 
used Welch’s t, ANOVA, Mann–Whitney U, or Kruskal–Wallis tests according to 
data distribution. Categorical data were compared using chi-squared tests. A p-value 
of <0.05 was considered statistically significant; all tests were two sided. No 
adjustment was made for multiple comparisons. Parsimonious criterion-based model 
building used the following principles: relevant explanatory variables were identified 
from previous studies; interactions were checked at first order level; final model 
selection was informed by the Akaike Information Criterion (AIC) and c-statistic, 
with appropriate assumptions checked including the distribution of residuals.  
Analysis of symptom co-occurrence was performed using the Jaccard similarity 
coefficient and presented as a hierarchically ordered heatmap. Statistical analyses 
were performed using R (R Core Team version 3.6.3, Vienna, Austria) with packages 
including tidyverse, finalfit  lubridate, ggplot2, gplot, dendextend and UpSetR. 
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Patient and public involvement  
This was an urgent public health research study in response to a Public Health 
Emergency of International Concern. Patients or the public were not involved in the 
design, conduct, or reporting of this rapid response research. 
 
Results 
451 patients under 19 years with laboratory-confirmed SARS-CoV-2 (451/55 092, 
0.8% of total cohort) were enrolled at 116 hospitals in England, Scotland, and Wales 
between 17 January and 5 June 2020, and 55 092 people of all ages were admitted to 
260 hospitals. (Error! Reference source not found. and Supp Figures 1 and 2).  
Age, sex and ethnicity 
The median age of the children was 3.9 years [IQR 0.3-12.9 years] and 57% 
(256/450) were male. Ethnicity was recorded in 89% (401/451) of cases: 56% 
(224/401) were White, 12% (49/401) were South Asian and 10% (40/401) were of 
Black ethnicity. At least one comorbidity was reported in 43% (195/451).  
Symptoms 
The most common presenting symptoms were fever (73%, 306/418), cough (43%, 
175/408), shortness of breath (32%, 124/389) and nausea/vomiting (32%, 120/380, 
Error! Reference source not found., upper panel). Fever, cough and shortness of 
breath did not show an association with age, however nausea and vomiting, 
abdominal pain, headache, and sore throat showed an increasing trend with age (Supp 
Figure 4).  A heatmap and dendrogram of presenting symptoms revealed distinct 
clusters of clinical sub-phenotypes (Error! Reference source not found., lower panel). 
These comprised a  respiratory illness, with clustering of both upper and lower 
respiratory symptoms together (light green and brown clusters) in addition to a cluster 
representing a muco-enteric illness (orange clusters). The latter cluster contained the 
symptoms specified in the WHO preliminary case definition for MIS-C (diarrhoea, 
abdominal pain, vomiting, rash and conjunctivitis) in addition to fatigue and 
headache. The two main clusters were not entirely dichotomous, and the muco-enteric 
cluster showed some overlap with upper respiratory tract symptoms (light green 
cluster), but very little overlap with the lower respiratory tract symptoms of wheeze 
and lower chest wall indrawing (brown cluster).  
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 17, 2020. .https://doi.org/10.1101/2020.07.14.20153320doi: medRxiv preprint 
 13
Comorbidities 
The most common comorbidities were neurological (12%, 51/419), 
haematological/oncological/immunological (combined category as described in Supp 
Methods, 8%, 35/420) and cardiac (7%, 31/416). Data on prematurity (defined as 
being born before completion of 37 weeks gestation) was only routinely collected for 
children aged under 1 year old and 22% (32/148) were premature (Supp Table 1 and 
Supp Figure 3).  
The median PEWS at presentation was 3 [IQR 1.0-5.0] and blood tests at presentation 
were mainly within normal ranges (Supp Tables 2 and 3). Antibiotics were given to 
71% (281/397) of children and 7% (26/368) received antiviral medication (22 
received acyclovir and 4 received remdesivir, Table 2).  
 
Children requiring critical care 
17% of children (72/431) were admitted to critical care (ICU or HDU level care); 5% 
(12/240) received inotropic support, 7% (28/408) received non-invasive ventilation 
and 9% (35/408) received invasive mechanical ventilation (Tables 2, Table 3 and 
Supp Figure 5). Black ethnicity was significantly associated with admission to 
critical care on multivariable analysis (odds ratio (OR) 3.02 (95% confidence interval 
1.30 to 6.84, p=0.008 Table 4 and Supp Table 4). On multivariable analysis, both 
age under one month (OR 5.05 (1.69 to 15.72, P=0.004)) and age between 10-14 
years (OR 3.11 (1.21 to 8.55, p=0.022))  were associated with admission to critical 
care (reference age group 15 to 19 years), but there was no association with sex on 
either univariable or multivariable analysis (Table 3, Table 4 and Supp Table 4). 
On univariable analysis, children with comorbidities were more likely to be admitted 
to critical care than those without (OR 1.90 (1.14 to 3.19, p=0.014) however, this no 
longer reached significance in the multivariable model (OR 1.72 (0.95 to 3.26, p = 
0.074). Comorbidities most commonly associated with critical care admission on 
univariable analysis were prematurity (48% (11/23) critical care admissions vs 18% 
(21/120) of standard care admissions, p=0.005), obesity (8% (6/71) vs 2% (7/338), 
p=0.014) and gastrointestinal comorbidities (7% (5/72) vs 1% (5/342), p=0.017, 
Table 3 and Supp Table 5). Children receiving critical care were more likely to have 
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been admitted to hospital more than 5 days before their symptoms started (indicating 
likely hospital acquired infection) than those receiving ward level care (15/71 (21%) 
vs 27/344 (8%) p=0.002). No association was seen between prior immunosuppressant 
use and critical care admission (Error! Reference source not found.). 
Children admitted to critical care were more likely to have presented with diarrhoea, 
(35% (22/63) vs 12% (36/309), p <0.001), conjunctivitis (13% (8/62) vs 2% (6/285), 
p=0.001) and confusion (22% (13/60) vs 7% (20/302), p=0.001) than those cared for 
on a standard ward (Supp Table 6). They were objectively more unwell at 
presentation than those receiving standard ward care (median PEWS of 5 [IQR 3.0- 
8.0] vs 2 [1.0-4.0], p<0.001, Supp Table 7). There were also significant differences 
in haematologic, biochemical and radiologic abnormalities between the two groups at 
presentation (Supp Table 8). In particular, children admitted to critical care had a 
lower platelet count (median 206.5 x109/L [IQR 129.0-296.8] vs 298.0 x109/L [233.0-
387.0], p <0.001), a higher neutrophil count (7.5 x109/L [4.8-13.0] vs 4.6 x109/L [2.3-
8.3], p <0.001) and higher CRP (66.0mg/L [7.0-211.3] vs 12.0mg/L [4.0-58.0], 
p<0.001) at presentation than those cared for on a standard ward. Children admitted to 
critical care were also more likely to have infiltrates on chest radiograph (64% (32/50) 
vs 34% (38/112), p <0.001). 
Patient outcomes 
Overall, 83% (373/451) of children and young people were discharged alive, 0.7% 
(3/451) died, and 17% (75/451) continued to receive care at the date of reporting or 
were missing outcomes (Table 2). 
There were no deaths in children under 16 years of age in this cohort. Three young 
people died, who were 16 to 19 years. Two of these young people had profound 
neurodisability with pre-existing respiratory compromise. The third young person was 
immunosuppressed by chemotherapy for a haematological malignancy. 
 
 Patients meeting the WHO preliminary case definition for MIS-C 
Twelve per cent (36/303) of children met the WHO preliminary case definition for 
MIS-C (17) (Table 5 and Supp Figure 6). The first patient identified developed 
symptoms in mid-March, when covid-19 cases were increasing nationally, followed 
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by a small number of cases identified steadily throughout the surveillance period 
(Figure 2). Geographically, the highest number of children with MIS-C came from 
areas with the largest covid-19 outbreaks, namely the Midlands and London (Supp 
Figure 7). 
Children meeting the WHO preliminary definition for MIS-C were significantly older 
than those who did not (median 10.8 years [IQR 8.4-14.1] vs 2.0 [0.2-12.6], p<0.001) 
and were significantly more likely to be of non-White ethnicity (70% (23/33) vs 43% 
(101/237), p=0.005, Table 5). MIS-C was not associated with comorbidity (Supp 
Table 9). In addition to the WHO case definition features (fever, rash, conjunctivitis 
and gastrointestinal symptoms), the children with MIS-C were also more likely to 
present with headache (45% (13/29) vs 11% (19/171), p<0.001), myalgia (39% 
(11/28) vs 7% (12/170), p<0.001) lymphadenopathy (21% (6/29) vs 3% (6/210), 
p=0.001), sore throat (37% (10/27) vs (13% (24/183), p = 0.004) and fatigue (57% 
(17/30) vs 31% (60/192), p=0.012) than children who did not (Supp Table 10). 
Children with MIS-C also had a higher PEWS score at presentation (median 5.5 [IQR 
3.0-7.0] vs 3.0 [1.0-5.0], p<0.001) and were more likely to have reduced 
consciousness (32% (10/31) vs 9% (17/200), p=0.001) than those who did not meet 
the criteria (Supp Table 11 and Supp Figure 8).  
Review of laboratory investigations found that children meeting the criteria for MIS-
C were more likely to have a platelet count of less than 150 x109/L than those who did 
not (30% (10/33) vs 10% (24/232), p=0.004, Supp Table 12). Children meeting the 
MIS-C criteria also had lower lymphocyte counts (median 0.9 x 109/L [IQR 0.7-1.8] 
vs 2.1 x 109/L [1.4-3.6], p<0.001) but higher neutrophil counts (7.8 x 109/L [5.7-12.3] 
vs 5.1 x 109/L [2.3-9.3], p=0.001) and higher creatinine (57.0 μmol/L [38.0-74.8] vs 
28.0 μmol/L [20.0-46.0], p<0.001) than those without (Supp Table 12).  
Children with MIS-C were four times more likely to be admitted to critical care (61% 
(22/36) vs 15% (40/267, p<0.001, Table 5). They were more likely to receive 
intravenous corticosteroids (47%, (14/30) vs 4% (9/226) p <0.001), non-invasive 
(25% (9/36) vs 6% (14/254), p=0.001) and invasive ventilation (25% (9/36) vs 9% 
(22/254), p=0.007) as well as inotropic support (28% (5/18) vs 4% (6/144), p=0.003, 
Table 5). There were no deaths in the MIS-C group.  
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Discussion 
Principal Findings 
There were 451 children and young people under 19 years with laboratory confirmed 
SARS-CoV-2 recruited to the ISARIC WHO CCP-UK study between 17 January  and 
5 June 2020, accounting for 0.8% of all patients in the whole cohort at that time. The 
median age of children with covid-19 was 3.9 years [IQR 0.3-12.9]. The cohort was 
predominantly male (57%) and of White ethnicity (56%) with most (57%) children 
having no known comorbidities. The most common presenting symptoms were fever, 
cough, shortness of breath, nausea and vomiting and a clear muco-enteric cluster of 
symptoms was seen. Seventeen percent of hospitalised children required critical care. 
Critical care admission was associated with age younger than one month, age 10 to 14 
years and Black ethnicity. The in-hospital case fatality rate was strikingly low (3 
patients, 0.7%) when compared with 25% (14 025 / 55 092)  across all age groups in 
the cohort with covid-19 for the same time period. In this paediatric cohort, 12% of 
patients met the WHO preliminary criteria for MIS-C, which was associated with 
older age, non-White ethnicity and admission to critical care. MIS-C cases were first 
identified in mid-March when cases of covid-19 began to rise in the UK. In addition 
to the clinical criteria provide by the WHO, we found children with MIS-C were more 
likely to present with headache, myalgia, fatigue, sore throat and lymphadenopathy as 
well as a lower platelet count than children with SARS-CoV-2 who did not meet the 
MIS-C criteria. 
Strengths and limitations of this study 
This study is unique in that data for patients with laboratory-confirmed covid-19 were 
collected prospectively and throughout the admission. The ISARIC WHO CCP-UK 
study had previously been activated in 2016 and 2018 for cases of Middle East 
Respiratory Syndrome (MERS) and monkeypox so was prepared for the SARS-CoV-
2 pandemic, allowing swift activation. Consequently, in addition to reporting the 
clinical characteristics, risk factors and outcomes of covid-19 in children, this dataset 
provided a unique opportunity to objectively monitor the emergence and progression 
of a novel multisystem inflammatory syndrome in the UK, whilst minimising recall 
bias. The first patient meeting the criteria for MIS-C was identified on 19 March 
2020, whilst the first published cases were reported on 6 May 2020 [8]. Comparison 
with overall covid-19 cases confirms the sporadic occurrence of the MIS-C 
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throughout the first peak of the covid-19 pandemic in the UK. In contrast to previous 
reports, our analysis was limited only to children admitted with laboratory confirmed 
SARS-CoV-2 which allowed us to clearly define the picture of covid-19 in children 
and reduce confounding with other potential causes.  
The ISARIC WHO CCP-UK database is estimated to represent 53% of covid-19 
hospitalisations across England, Wales and Scotland. It is therefore susceptible to 
selection bias, particularly as tertiary centres with critical care units and specialist 
children’s hospitals are more likely to have dedicated research teams, potentially 
skewing the severity and age of the patients reported. 
The most common presenting symptoms in children in our study (fever, cough and 
dyspnoea) reflect the original case definition for SARS-CoV-2 testing in the UK, 
suggesting that this paediatric cohort is likely to have been influenced by the testing 
criteria.  
The PEWS is validated up to 16 years of age [14]. As ranges of clinical observations 
do not vary considerably between 16 and 18 year olds [17] PEWS scoring was 
extended to all those under 19 years. To identify children and young people meeting 
the WHO criteria for MIS-C it is necessary to have data on CRP and fever. Decisions 
to measure CRP and other parameters were at physicians’ discretion. Children 
missing either of these variables were excluded from this analysis.  
A limitation of this study is the use of a case record form that was agnostic to age so 
not specifically tailored for paediatric data collection, particularly in regard to 
comorbidities. Some of this information was available in free text but these data were 
incomplete. By design we are not able to differentiate between people whose 
symptoms were directly attributable to SARS-CoV-2 infection and those who had 
been admitted for other reasons and then found to be positive for the virus. The study 
relied primarily on PCR testing as evidence of SARS-CoV-2 infection as diagnostic 
serology was not widely available at the start of the pandemic. As other studies of 
MIS-C report several children who are PCR-negative but have serological evidence of 
infection, this could have limited early recruitment of MIS-C cases. Finally, in order 
to share findings from this study promptly as an urgent public health research priority, 
these analyses were performed on a cohort with ongoing data collection and missing 
data, the proportion of which will decrease with time. We do not have data for 
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children identified as infected with SARS-CoV-2 in the community who were not 
admitted to hospital, and we cannot yet report on sequelae of covid-19 in children 
after discharge. 
Comparison with other studies 
Children and young people under 19 years accounted for 0.8% (451/55 394) of the 
ISARIC WHO CCP-UK cohort on 5 June 5 2020, which is broadly consistent with 
2% reported in China [1] and 1.7% in North America [2]. Our cohort of paediatric 
hospitalised cases had a median age of 3.9 years which was similar to an Italian 
cohort (3.3 years [18]), but younger than Chinese (6-7 years) [5,6] and North 
American (11 years) cohorts [2], however these other cohorts were not limited to 
hospitalised children. While respiratory presentations were most common, 35% of 
children also had gastrointestinal symptoms at presentation, which is higher than 10-
22% reported in other paediatric literature [2,18,19]. Gastrointestinal symptoms have 
also been prominent in children presenting with infection by MERS-CoV (28%) [20] 
and severe acute respiratory syndrome coronavirus (30%) [21]. We also identify for 
the first time a clear muco-enteric cluster of symptoms which shows some overlap 
with upper, but not lower respiratory tract symptoms.  
Children of Black ethnicity were over-represented, comprising 10% of our paediatric 
cohort compared with 4.7% of all children under 18 years across England and Wales 
[22] and 1% in Scotland [23]. This finding may also be influenced by the ethnic 
composition of the population served by the sites recruiting to this study. Black 
ethnicity was also associated with increased odds of admission to critical care on 
multivariable analysis, consistent with reports for adult populations suggesting South 
Asian and Black ethnicities are disproportionately severely affected by SARS-CoV-2 
infection [24–26]. Studies of paediatric covid-19 from other countries have either 
been from ethnically homogenous groups or have not reported ethnicity, making 
comparisons difficult.  
The critical care admission rate in our cohort was 17% compared to 10% reported in a 
north American cohort of hospitalised children [2] and 13% in a multicentre cohort 
study across 25 European countries [19]. As previously noted, this rate may be 
elevated in our study owing to hospitals with dedicated paediatric research teams 
being more likely to provide paediatric critical care. The prevalence of comorbidities 
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(53%) in children admitted to critical care in our cohort was also similar to that 
reported in the European multicentre study countries (52% [19]). Obesity was 
associated with critical care admission in our paediatric cohort, in agreement with 
adult data from ISARIC WHO CCP-UK [13]. In England 20% of children are obese 
by 11 years of age [27]. Childhood obesity, however, is also influenced by 
deprivation [27], which was not analysed in our study. Age under 1 month was 
associated with increased odds of critical care admission, in agreement with the 
European cohort [19]. As previously noted, a limitation of our study was the difficulty 
in differentiating between children with symptoms directly attributable to SARS-
CoV-2 infection and those admitted for other reasons and subsequently testing 
positive for the virus. This may explain the association between age under one month 
and admission to critical care, if these babies were already admitted to neonatal 
intensive care and undergoing regular SARS-CoV-2 screening. Children who had 
been admitted to hospital for more than 5 days prior to symptoms were also more 
likely to be admitted to critical care. By definition, this group includes children with 
comorbidity. SARS-CoV-2 nosocomial infections in children are not well reported 
and this area requires closer scrutiny, ideally with the use of viral sequence data.  
Using adapted WHO criteria [9], we identified 36 patients meeting the criteria for 
multisystem inflammatory syndrome. Initial UK reports described children admitted 
to hospital with circulatory shock and a hyperinflammatory state with features of 
similar to toxic shock or Kawasaki disease [8]. Children fulfilling the case definition 
for MIS-C have been reported in multiple regions experiencing large outbreaks of 
covid-19, including England (UK) [28], Paris (France) [11], Bergamo (Italy) [10] and 
New York City (USA) [29]. Ours is the first report, however, to identify cases and 
timelines using a prospective national data collection strategy. MIS-C appears to be 
temporally associated with covid-19 but a causal relationship remains to be 
established. Older age and non-White ethnicity were associated with MIS-C in our 
study, in agreement with a recent case series of 99 children with MIS-C from New 
York State (USA) where 63% were of non-White ethnicity and 69% were between 6 
and 20 years [29]. Children in our study with MIS-C were much more unwell than 
other children with covid-19, with 28% requiring inotropic support, (compared with 
20% in the Italian cohort[10], 47% in the French cohort [11] and 62% in the New 
York cohort [29].  
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Across the whole of our paediatric cohort, we identified a distinct cluster presenting 
with muco-enteric symptoms (rash, conjunctivitis, diarrhoea, vomiting and abdominal 
pain) in addition to headache and fatigue which overlapped very closely with the 
WHO preliminary case definition [9], suggesting that children with MIS-C may be at 
the severe end of this muco-enteric spectrum. The significant associations between 
MIS-C and headache, myalgia, fatigue, sore throat and lymphadenopathy in our 
cohort may be useful in refining the case definition. In addition, the association of 
MIS-C with platelet count less than 150 x109/L and low lymphocyte counts is in 
agreement with previous reports [28,29]. These important findings may assist in 
differentiating this syndrome from other illnesses, particularly Kawasaki disease 
where platelet counts are typically elevated. 
Conclusion and policy implications 
Our data confirms less severe covid-19 in children and young people with SARS-
CoV-2 infection than in adults. Admission to critical care was associated with age 
under 1 month, age 10-14 years and Black ethnicity. In agreement with previous 
reports, we find older age and non-White ethnicity to be associated with MIS-C. In 
addition, we provide evidence for refining the case definition for MIS-C including an 
association with low platelet count, headache, myalgia, lymphadenopathy, sore throat 
and fatigue which could be incorporated into future iterations of the case definition. 
The identification of a muco-enteric symptom cluster across the whole cohort also 
raises the suggestion that MIS-C may be the severe end of a spectrum of disease.  
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Summary box 
What is already known on this topic: 
The literature to date has consistently reported that children are less severely affected 
by SARS-CoV-2 infection than adults. Consequently, there is a less information 
regarding ethnicity, comorbidities, clinical and laboratory findings in children with 
SARS-CoV-2. A Multisystem Inflammatory Syndrome in Children and Adolescents 
(MIS-C) temporally associated with SARS-CoV-2 has been widely reported, however 
all reports to date arise from retrospective cases series which are vulnerable to recall 
bias.  
 
What this study adds : 
This is a large prospective cohort study of children admitted to hospital with 
laboratory-confirmed covid-19 and the first with prospective recruitment to examine 
MIS-C. Severe disease was rare and death exceptionally rare, and then occurred in 
older children with profound co-morbidity. We find that MIS-C cases have been 
present for longer than reported.  
Ethnicity appears to be a factor both in critical care admission and MIS-C. This cohort 
has also enabled identification of additional clinical (headache, myalgia, fatigue, sore 
throat and lymphadenopathy) and laboratory characteristics (including low platelets) 
which may help to refine the WHO criteria for MIS-C. 
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End material 
The study protocol is available at http://isaric4c.net/protocols; study registry 
https://www.isrctn.com/ISRCTN66726260. 
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List of Figures: 
Figure 1. Upper Panel  – Proportion of patients presenting with each symptom.  
Figure 1. Lower Panel -  Heatmap with dendrogram describing the clusters of co-
occurring symptoms calculated using hierarchical clustering with Jaccard distance as 
metric and complete linkage.  Heatmap displays the pairwise Jaccard indices among 
22 symptoms. Jaccard index is a measure of similarity that computes the ratio of the 
number of times two symptoms appear together in the data and the number of times 
either of them appear in the data. The index varies between 0 and 1 with 0 implying 
that the two symptoms never appear together (no co-occurrence), and 1 implying that 
the two symptoms only appear together (co-occurrence only). The dendrogram 
describing the clusters of symptoms in the heatmap was calculated using hierarchical 
clustering with Jaccard distance as metric and complete linkage, where Jaccard 
distance is calculated by subtracting the Jaccard index from 1. Conjunc = 
conjunctivitis. Lower chest = lower chest wall indrawing. Lymp = lymphadenopathy 
Figure 2 - Dates of symptom onset for paediatric cases of SARS-CoV-2 infection and 
cases meeting the WHO preliminary criteria for Multisystem Inflammatory Syndrome 
in Children and Adolescents (MIS-C) in the ISARIC WHO CCP-UK cohort over 
time. 
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Tables: 
 
Table 1. Demographics across the cohort of patients under 19 years with laboratory 
confirmation of SARS-CoV-2. Immunosuppressant use includes oral but not inhaled 
corticosteroids. Prematurity defined as birth before completion of  37 weeks gestation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable Level n (%) 
Total N (%)  451 (100.0) 
Age on admission (years) Median (IQR) 3.9 (0.3 to 12.9) 
Age (years) < 1 m 30 (6.7) 
 ≥1 m <1 yr 132 (29.3) 
 1-4 74 (16.4) 
 5-9 65 (14.4) 
 10-14 67 (14.9) 
 15-19 83 (18.4) 
Sex at Birth Male 256 (56.8) 
 Female 194 (43.0) 
 (Missing) 1 (0.2) 
Ethnicity White 224 (49.7) 
 Black 40 (8.9) 
 East Asian 10 (2.2) 
 South Asian 49 (10.9) 
 Other 78 (17.3) 
 (Missing) 50 (11.1) 
Admitted > 5 days before symptom onset No 385 (85.4) 
 Yes 42 (9.3) 
 (Missing) 24 (5.3) 
Any comorbidity No/Unknown 256 (56.8) 
 Yes 195 (43.2) 
Neurological No 368 (81.6) 
 Yes 51 (11.3) 
 (Missing) 32 (7.1) 
Haematology / Oncology / Immunology No 385 (85.4) 
 Yes 35 (7.8) 
 (Missing) 31 (6.9) 
Prematurity No 116 (25.7) 
 Yes 32 (7.1) 
 (Missing) 303 (67.2) 
Immunosuppressant use prior to presentation No 372 (82.5) 
 Yes 38 (8.4) 
 (Missing) 41 (9.1) 
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Table 2. Treatments received and outcomes. ICU/HDU = Intensive care unit / high 
dependency unit. ECMO = Extracorporeal membrane oxygenation 
Variable Level n (%) 
Total N (%)  451 (100.0) 
Antibiotic medication No 116 (25.7) 
 Yes 281 (62.3) 
 (Missing) 54 (12.0) 
IV steroid No 339 (75.2) 
 Yes 26 (5.8) 
 (Missing) 86 (19.1) 
Oral steroid No 339 (75.2) 
 Yes 15 (3.3) 
 (Missing) 97 (21.5) 
Antiviral medication No 360 (79.8) 
 Yes 26 (5.8) 
 (Missing) 65 (14.4) 
Supplementary oxygen No 308 (68.3) 
 Yes 120 (26.6) 
 (Missing) 23 (5.1) 
High flow nasal cannula oxygen No 368 (81.6) 
 Yes 40 (8.9) 
 (Missing) 43 (9.5) 
Non-invasive ventilation No 380 (84.3) 
 Yes 28 (6.2) 
 (Missing) 43 (9.5) 
Invasive ventilation No 373 (82.7) 
 Yes 35 (7.8) 
 (Missing) 43 (9.5) 
Inotropic support No 228 (50.6) 
 Yes 12 (2.7) 
 (Missing) 211 (46.8) 
Nursed prone No 225 (49.9) 
 Yes 8 (1.8) 
 (Missing) 218 (48.3) 
Nitric oxide No 232 (51.4) 
 Yes 3 (0.7) 
 (Missing) 216 (47.9) 
ECMO No 403 (89.4) 
 Yes 3 (0.7) 
 (Missing) 45 (10.0) 
ICU/HDU admission No 359 (79.6) 
 Yes 72 (16.0) 
 (Missing) 20 (4.4) 
Outcome Died 3 (0.7) 
 Discharged alive 373 (82.7) 
 (Missing) 75 (16.6) 
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Table 3. Demographics stratified by admission to critical care. Categorical variables 
analysed using Fisher’s exact test, continuous variables by Kruskal Wallis test. 
Variable Level 
Standard ward 
Admission 
Critical care 
admission P 
Total N (%)  359 (83.3) 72 (16.7)  
Age on admission (years) Median (IQR) 3.4 (0.3 to 12.8) 8.7 (0.3 to 13.5) 0.646 
Neonate (< 1 month) No 339 (94.4) 62 (86.1) 0.020 
 Yes 20 (5.6) 10 (13.9)  
Age (years) <1 132 (36.8) 22 (30.6) 0.046 
 1-4 62 (17.3) 9 (12.5)  
 5-9 51 (14.2) 11 (15.3)  
 10-14 43 (12.0) 19 (26.4)  
 15-19 71 (19.8) 11 (15.3)  
Sex at Birth Male 200 (55.7) 44 (61.1) 0.437 
 Female 158 (44.0) 28 (38.9)  
 (Missing) 1 (0.3) 0 (0.0)  
Ethnicity White 191 (53.2) 27 (37.5) 0.038 
 Black 27 (7.5) 13 (18.1)  
 East Asian 9 (2.5) 1 (1.4)  
 South Asian 34 (9.5) 8 (11.1)  
 Other 62 (17.3) 12 (16.7)  
 (Missing) 36 (10.0) 11 (15.3)  
Admitted > 5 days before symptom onset No 317 (88.3) 56 (77.8) 0.002 
 Yes 27 (7.5) 15 (20.8)  
 (Missing) 15 (4.2) 1 (1.4)  
Any comorbidity No/Unknown 207 (57.7) 30 (41.7) 0.014 
 Yes 152 (42.3) 42 (58.3)  
Prematurity No 99 (27.6) 12 (16.7) 0.005 
 Yes 21 (5.8) 11 (15.3)  
 (Missing) 239 (66.6) 49 (68.1)  
Obesity No 331 (92.2) 65 (90.3) 0.014 
 Yes 7 (1.9) 6 (8.3)  
 (Missing) 21 (5.8) 1 (1.4)  
Gastrointestinal No 337 (93.9) 67 (93.1) 0.017 
 Yes 5 (1.4) 5 (6.9)  
 (Missing) 17 (4.7) 0 (0.0)  
Immunosuppressant use prior to 
presentation 
No 311 (86.6) 59 (81.9) 0.489 
 Yes 30 (8.4) 8 (11.1)  
 (Missing) 18 (5.0) 5 (6.9)  
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Table 4.  Factors associated with admission to critical care unit. Univariable and multivariable logistic regression analyses were performed using 
potential predictors identified a priori and during exploratory analyses. Results are odds ratios with 95% confidence intervals. Data are otherwise 
n (%). OR, odds ratio; m, month; yr, year; . OR, odds ratio with 95% confidence intervals 
 
  
Standard ward  
admission 
Critical care 
admission OR (univariable) OR (multivariable) 
Sex at Birth Male 200 (82.0) 44 (18.0) - - 
 Female 158 (84.9) 28 (15.1) 0.81 (0.48-1.34, p=0.413) 0.77 (0.42-1.39, p=0.397) 
Age (years) < 1 m 20 (66.7) 10 (33.3) 3.23 (1.19-8.77, p=0.020) 5.05 (1.69-15.72, p=0.004) 
 ≥1 m <1 yr 112 (90.3) 12 (9.7) 0.69 (0.29-1.67, p=0.406) 0.75 (0.26-2.19, p=0.598) 
 1-4 61 (87.1) 9 (12.9) 0.95 (0.36-2.45, p=0.919) 1.16 (0.39-3.44, p=0.787) 
 5-9 51 (82.3) 11 (17.7) 1.39 (0.56-3.49, p=0.476) 1.38 (0.47-4.07, p=0.551) 
 10-14 43 (69.4) 19 (30.6) 2.85 (1.26-6.75, p=0.014) 3.11 (1.21-8.55, p=0.022) 
 15-19 71 (86.6) 11 (13.4) - - 
Ethnicity White 190 (87.6) 27 (12.4) - - 
 Black 27 (67.5) 13 (32.5) 3.39 (1.53-7.29, p=0.002) 3.02 (1.30-6.84, p=0.008) 
 East Asian 9 (90.0) 1 (10.0) 0.78 (0.04-4.41, p=0.819) 0.64 (0.03-3.95, p=0.687) 
 South Asian 34 (81.0) 8 (19.0) 1.66 (0.66-3.82, p=0.256) 1.56 (0.60-3.76, p=0.340) 
 Other 62 (83.8) 12 (16.2) 1.36 (0.63-2.80, p=0.412) 1.31 (0.59-2.78, p=0.492) 
Any comorbidity No/Unknown 206 (87.3) 30 (12.7) - - 
 Yes 152 (78.4) 42 (21.6) 1.90 (1.14-3.19, p=0.014) 1.72 (0.95-3.16, p=0.074) 
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Table 5. Demographics at presentation and therapies administered stratified by 
Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) status. 
Categorical variables analysed using Fisher’s exact test, continuous variables by 
Kruskal Wallis test. 
 
Variable Level 
Did not meet 
MIS-C criteria 
Met MIS-C 
criteria p 
Total N (%)  267 (88.1) 36 (11.9)  
Age on admission (years) Median (IQR) 2.0 (0.2 to 12.6) 10.8 (8.4 to 14.1) <0.001 
Age (years) <1 111 (41.6) 2 (5.6) <0.001 
 1-4 45 (16.9) 4 (11.1)  
 5-9 30 (11.2) 10 (27.8)  
 10-14 33 (12.4) 12 (33.3)  
 15-19 48 (18.0) 8 (22.2)  
Sex at Birth Male 166 (62.2) 22 (61.1) 1.000 
 Female 101 (37.8) 14 (38.9)  
 (Missing) 0 (0.0) 0 (0.0)  
Ethnicity White 136 (50.9) 10 (27.8) 0.020 
 Black 25 (9.4) 6 (16.7)  
 East Asian 4 (1.5) 1 (2.8)  
 South Asian 28 (10.5) 4 (11.1)  
 Other 44 (16.5) 12 (33.3)  
 (Missing) 30 (11.2) 3 (8.3)  
White ethnicity Non-White 101 (37.8) 23 (63.9) 0.005 
 White 136 (50.9) 10 (27.8)  
 (Missing) 30 (11.2) 3 (8.3)  
Any comorbidity No/Unknown 151 (56.6) 20 (55.6) 1.000 
 Yes 116 (43.4) 16 (44.4)  
Immunosuppressant use prior to 
presentation 
No 234 (87.6) 30 (83.3) 0.219 
 Yes 21 (7.9) 5 (13.9)  
 (Missing) 12 (4.5) 1 (2.8)  
Admitted > 5 days before symptom 
onset 
No 236 (88.4) 33 (91.7) 1.000 
 Yes 25 (9.4) 3 (8.3)  
 (Missing) 6 (2.2) 0 (0.0)  
IV steroid No 217 (81.3) 16 (44.4) <0.001 
 Yes 9 (3.4) 14 (38.9)  
 (Missing) 41 (15.4) 6 (16.7)  
High flow nasal cannula oxygen No 234 (87.6) 19 (52.8) <0.001 
 Yes 20 (7.5) 17 (47.2)  
 (Missing) 13 (4.9) 0 (0.0)  
Non-invasive ventilation No 240 (89.9) 27 (75.0) 0.001 
 Yes 14 (5.2) 9 (25.0)  
 (Missing) 13 (4.9) 0 (0.0)  
Invasive ventilation No 232 (86.9) 27 (75.0) 0.007 
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 Yes 22 (8.2) 9 (25.0)  
 (Missing) 13 (4.9) 0 (0.0)  
Inotropic support No 138 (51.7) 13 (36.1) 0.003 
 Yes 6 (2.2) 5 (13.9)  
 (Missing) 123 (46.1) 18 (50.0)  
ICU/HDU admission No 227 (85.0) 14 (38.9) <0.001 
 Yes 40 (15.0) 22 (61.1)  
 (Missing) 0 (0.0) 0 (0.0)  
Outcome Died 2 (0.7) 0 (0.0) 1.000 
 Discharged alive 231 (86.5) 27 (75.0)  
 (Missing) 34 (12.7) 9 (25.0)  
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